Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing the stock's recent struggles.

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

It’s been nearly two years since the FDA approved their use in kids, but some are questioning if these drugs are safe for ...

A recent study showed that well-known diabetes and weight loss drugs such as Ozempic and Wegovy do not raise the risk of ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California’s health insurance for low-income people under ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

There are plenty of people taking Ozempic to lose weight, but Doctor Giles Yeo has explained the main problem people have ...